Cancer stem cells are considered as an origin of cancer.Cancer stem cells can cause tumors in mice models.Recent studies proved the efficacy of some promising therapies to treat cancers.Dendritic cell (DC) therapy is one of the best promising therapies to treat cancer.In recent years, DC therapy is performed by using primed cancer cell antigens of DC to immune organism body.This research aims to combine DC therapy with breast cancer stem cell (BCSC)antigen for treating breast cancer and compare the treatment efficacy of DC therapies with BCSCs and breast cancer cells derived antigens in murine models.DCs were derived from mouse bone marrow monocytes.Then they were loaded with the breast cancer cell antigen prior to employ into the tumor mice model.This was performed to determine whether the DCs would capture and eventually migrate, be present in the spleen and present the cancer antigens to autologous CD8 T cells;induce the activation of the CTL response.The existence and size of tumors in mice was evaluated after 15-60 days from transplantation.The results showed that 5/15;10/15, 5/15 mice of the experimental group with injected BCSC antigen, breast cancer antigen, and BCSC-breast cancer antigen mixture loaded DCs respectively got tumors after 20 transplantation days.While in control group 15/15 mice got tumors after 10 transplantation days.It is also noticed that transplanted DCs could migrate into spleen, stimulate CD8 T ceils and CD45 T cells proliferation.Specially, the ratio of CD8 T cells strongly increased in comparison to control or normal mice.These results are important and provides most required initial platform to do further experiment.Results of this study also established a promising novel targeting therapy for cancer, especially for breast cancer.